Hyloris Pharmaceuticals SA (EBR:HYL)

Belgium flag Belgium · Delayed Price · Currency is EUR
5.34
-0.06 (-1.11%)
Apr 28, 2026, 5:17 PM CET
-15.24%
Market Cap 149.52M
Revenue (ttm) 8.83M
Net Income (ttm) -6.33M
Shares Out 28.00M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,248
Average Volume 8,571
Open 5.24
Previous Close 5.40
Day's Range 5.22 - 5.34
52-Week Range 4.51 - 8.40
Beta 0.66
RSI 46.51
Earnings Date Apr 30, 2026

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortal... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 50
Stock Exchange Euronext Brussels
Ticker Symbol HYL
Full Company Profile

Financial Performance

In 2025, Hyloris Pharmaceuticals's revenue was 8.83 million, a decrease of -9.50% compared to the previous year's 9.76 million. Losses were -6.33 million, -0.13% less than in 2024.

Financial Statements

News

There is no news available yet.